Compensated Awareness Post View
Disclaimer
Imprimis Pharmaceuticals, Inc. (IMMY) Thriving through the Art and Science of Compounding Pharmacy
If one were to begin a discussion on the history and future of pharmacy, they would not be able to proceed very far without addressing the prominent role pharmacy compounding has played and will play within the industry. Woven throughout thousands of years of history, the pharmacist was the one individual in society who carried the knowledge to prepare drugs from vegetable, animal, and mineral sources. As the industrial revolution evolved into the 1900’s, mass-production of drugs occurred along with its subsequent cookie cutter, one-size for everybody mindset. But as one could anticipate, with every action there is a reaction and thus fewer choices of dosage forms, dosage strengths, and less individualization of prescriptions became issues difficult to ignore. Pharmacy compounding today is now looked upon as a major role player in health care.
One perfect example of the unmistakable significance of compounding pharmacy includes the fact that health care today cannot exist without it. Adding to its relevance, observers should further note limited dosage forms and strengths are available from manufacturers, home health care requires individualized compounded medications, and innovative or new therapeutic approaches often are available only through compounding.
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has a business model and strategy centered on the pulse of real market demand for products produced through the art and science of compounding pharmacy. One of its central strategies is the use of compounding pharmacies to formulate proprietary compounded drug formulations and technologies and then distribute them to physicians and patients. Vital to the compounding process, physicians collaborate with pharmacists to reformulate FDA-approved drugs to meet a patient’s specific medical needs. IMMY is attentive to the ideas generated by pharmacists dealing directly with doctors and their patients to address specific, unmet patient needs while supporting the important role and contribution of the compounding pharmacist and compounding pharmacies in the U.S. healthcare system.
Imprimis Ophthalmic Anti-Inflammatory and Anti-Bacterial Combination Formulations
During the second half of 2013, the company acquired intellectual, proprietary property related to ophthalmic compounded formulations for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. These formulations incorporate patent-pending technologies which enable the combination of drugs such as triamcinolone and moxifloxacin that do not typically distribute evenly in a suspension. IMMY believes such formulations can potentially impact the fast-growing global cataract surgery drug market and other markets in ophthalmology for procedures where there is a risk of inflammation and infection. The company’s formulations have been used as an injection, but have also been used topically as an eye drop – both dependent on the procedure at hand. Through its use of new technology, Imprimis solutions offer doctors alternatives to address the primary ocular complications of ophthalmic surgery which include infection risk and inflammation following surgery.
Imprimis Dermatology and Urology Formulations
In addition to IMMY’s proprietary ophthalmic formulations, the company acquired intellectual property assets in the form of provisional patent applications related to topical formulations comprising tranexamic acid and an antibiotic which has been prescribed for wound healing, as well as injectable formulations comprising pentoxifylline for treatment of fibrotic conditions. The company is currently seeking to obtain additional supporting data with respect to these formulations as part of its assessment process. Although compounded formulations utilizing IMMY proprietary technology are currently available through Pharmacy Creations with a physician prescription, the company does not expect to market these non-ophthalmic formulations without a successful commercial assessment.
Imprimis Pharmaceuticals’ Mission
The company seeks to identify and assess the state of our current healthcare economy and solve unmet patient needs through the development and commercialization of proprietary sterile and topical drug formulations that have been prescribed by a physician and have shown promise for patients in clinical settings. Their ultimate goal is to deliver high quality, novel, and customizable medicines to physicians and patients affordably. As a result of the growing demand for the company’s “Dropless” formulations and the planned launch of its “Defeat IC” and related lido-hep compound, Imprimis is pursuing opportunities to expand its prescription dispensing capabilities aimed at reaching nationwide distribution for its formulations within the next six to nine months.
For more information, visit www.imprimispharma.com
